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Abstract 
Objective: We examined the usefulness of light-chain restriction on 
immunocytochemical double staining for cytological diagnosis. 
Study Design: We investigated light-chain restriction on immunocytochemical double 
staining in 40 patients with proliferative lymphatic disorders (B-cell lymphoma: 23 
patients, reactive lymphpoid lesions: 13, T-cell lymphoma: 2, and Hodgkin’s 
lymphoma: 2). In addition, the results of flow cytometry (FCM) were also compared in 
34 of these patients. 
Results: On immunocytochemical double staining, light-chain restriction was detected 
in 21 (91.3%) of 23 patients with B-cell lymphoma. On FCM, it was detected in 15 
(71.4%) of 21 patients with B-cell lymphoma. Neither immunocytochemical double 
staining nor FCM showed light-chain restriction in any patients with reactive lesions, 
T-cell lymphoma, or Hodgkin’s lymphoma. 
Conclusion: Immunocytochemical double staining facilitated the detection of 
light-chain restriction with a single specimen under morphological observation. The 
application of this procedure may improve the accuracy of cytological diagnosis. 
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Introduction 
Cytological diagnosis with fine needle aspiration is used for diagnosis in 
patients with lymph node swelling. However, it is difficult to differentiate between 
malignant lymphoma and benign lymphoid lesion in some patients. In particular, when 
low-grade B-cell lymphoma is mixed with a large number of reactive lymphocytes, 
cytological diagnosis is difficult [1-3]. 
For the differential diagnosis of between malignant lymphoma and benign 
lymphoid lesion, immunostaining and flow cytometry (FCM) are very important. In 
particular, in the diagnosis of low-grade B-cell lymphoma without cellular atypia, it is 
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diagnostically important to confirm immunoglobulin light-chain restriction [3-5]. To 
verify monoclonal features, a Kappa/Lambda light-chain restriction ratio of more than 3 
or Lambda/Kappa light-chain restriction ratio of more than 2 is recommended as a 
criterion [4,5, 6, 7, 8]. 
Immunocytochemical double staining (IDS) for cytological diagnosis 
facilitates the detection of light-chain restriction with a single slide under morphological 
observation. In this study, we detected light-chain restriction using IDS, compared the 
results with those of flow cytometry, and examined the usefulness of IDS for 
cytological diagnosis. 
 
Materials and Methods 
Case selection 
Samples were selected from records on cytological diagnosis in Kagawa 
Prefectural Central Hospital between 2009 and 2010. 
All data and samples from the patients were collected with their informed 
consent. 
The subjects consisted of 23 patients with B-cell lymphoma group (diffuse 
large B-cell lymphoma (DLBCL): 9 patients, follicular lymphoma: 8, 
lymphoplasmacytic lymphoma: 1, plasma cell myeloma: 1, mantle cell lymphoma: 1, 
Burkitt-like lymphoma: 1, and B-cell lymphoma NOS: 2). The  control  consisted of 
17 patients  with negative control group ( 2 with T-cell lymphoma (peripheral T-cell 
lymphoma: 1, and lymphoblastic lymphoma: 1), 2 with Hodgkin's lymphoma, and 13 
with reactive lesions).  
 
Specimen processing 
In 36 patients, cell suspension was prepared from biopsy specimens using fine 
needle aspiration. In 4, body cavity fluid was used. After all samples were washed in 
physiological saline, cells were smeared on slide glasses, and fixed in 95% ethanol. 
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Immunocytochemical double staining 
With respect to Kappa + Lambda antibody, reagents, and usage, a Biocare 
Medical kit (Concord, CA, U.S.A.) was employed. According to its protocol, staining 
was performed. 
The primary antibody consists of an antibody cocktail with mouse (kappa) 
and rabbit (lambda) light chains antibody. 
A cocktail of conjugated goat anti-rabbit polymer horseradish peroxidase 
(HRP) and conjugated goat anti-mouse polymer alkaline phosphatase (AP) secondary 
antibodies react simultaneously with a cocktail of a mouse and a rabbit primary 
antibody. 
 The staining method is as follows: 
1. Wash in Tris-Buffered Saline (TBS) wash buffer. 
2. Apply primary antibody cocktail for 30 minutes. 
3. Wash in TBS wash buffer. 
4. Apply secondary antibodies for 30 minutes. 
5. Wash in TBS wash buffer. 
6. Apply DAB for 2 minutes. 
7. Rinse in TBS. 
8. Apply Vulcan Fast Red for 15 minutes. 
9. Wash in deionize water. 
10. Apply Mayer's Hematoxylin for 1 minute. 
11. Wash in deionize water for 5 minutes. 
12. Dehydrate, clear and coverslip. 
 
Count 
The smallest lymphocytes were defined as small lymphocytes, 
and others as medium to large lymphocytes. 
          We randomly counted 500 lymphocytes at a magnification of 1,000. 
The cell size varied: small to large. Kappa (red)- and Lambda (brown)-stained cells 
were determined as a percentage of the above cells (IDS-1). In addition, we counted 200 
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middle- to large-sized cells appearing in each specimen (IDS-2). 
 
Diagnostic criteria on IDS 
The results of measurement were calculated so that the Kappa/Lambda or 
Lambda/Kappa ratio was 1 or more. As a diagnostic criterion for light-chain restriction 
(monoclonality), the cut-off value of Kappa/Lambda or Lambda/Kappa ratio was 
established as >3:1 by comparing our data with previous studies. [4,5,9]. 
 
Flow cytometry 
In 34 (85%) of the 40 patients, FCM was conducted. The following antibody 
panels were employed: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, IgM, 
CD25, CD30, CD34, CD38, CD45, CD56, and immunoglobulin light chains (Kappa, 
Lambda). 
 
Statistical analysis 
The results were compared between the B-cell lymphoma and light-chain 
restriction-negative control groups using the Mann-Whitney U test. The data were 
analyzed with the StatView software (version 5.0; SAS Institute, Inc., San Francisco, IL, 
U.S.A.).  
 
Results 
The results are shown in Table 1. In the negative control group (T-cell 
lymphoma, Hodgkin’s lymphoma, and reactive lymphoid lesions), the light-chain 
restriction (LCR) ratio was less than 3 in all patients regardless of procedures (range: 1 
to 2.1)(Table 2, Figure 1). There was a significant difference in comparison with the 
B-cell lymphoma group (P<0.0001).   
Of 21 patients with B-cell lymphoma in whom FCM was performed, 
light-chain restriction was detected in 15 (71.4%). Of 23 patients in whom IDS-1 was 
conducted, LCR was detected in 15 (65.2%) (Figure 2). Of 23 patients in whom IDS-2 
was conducted, LCR was detected in 21 (91.3%) (Table 3) . 
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When comparing the LCR detection rate in the 21 patients with B-cell 
lymphoma, there was no patient in whom LCR was detected on FCM, but not on 
IDS-1/-2. LCR was detected on both FCM and IDS in 15 patients (71.4%). In 4 (19.0%), 
LCR was not detected on FCM, but it was detected on IDS. In 2 (9.5%), neither FCM 
nor IDS showed LCR (Table 4). 
The sensitivities of FCM, IDS-1, and IDS-2 were 71.4, 65.2, and 91.3%, 
respectively. Their specificities were 100% (Table 5). 
 
Discussion 
Biopsy is frequently performed in patients with suspected malignant lymphoma. In a 
portion of each specimen, surface markers are investigated using FCM in many patients. 
Among these markers, the confirmation of surface immunoglobulin LCR is useful for 
the diagnosis of B-cell lymphoma. In formalin-fixed paraffin sections, which are usually 
used, only antigens existing in the cytoplasm can be accurately detected. As 
immunoglobulins on the cell surface are non-specifically fixed and soluble, it is difficult 
to verify LCR [10]. For this reason, surface immunoglobulins were examined using 
FCM. Subsequently, immunostaining is performed to detect immunoglobulins on the 
cell surface [9-12]. However to our best knowledge there are no reports on IDS. 
Therefore we examined this method.   
There are many criteria to establish the cut-off of LCR. Some criteria include 
a Kappa/Lambda ratio of 3 or more, or a Lambda/Kappa ratio of 2 or more. Others 
include that of 6 or more [2,3,4,6,8,11,12,13,14,15]. Sneige et al.[5] performed 
immunostaining using fine-needle aspiration samples, and regarded lesions with an 
LCR ratio of 6 or more as monoclonal or B-cell lymphoma. Lesions with an LCR ratio 
of 3 or less were regarded as “reactive lymphoid lesion”. Lesions with intermediate 
values were evaluated as “atypical lymphoid lesion”. They emphasized the necessity of 
biopsy or thorough follow-up. In our investigation, all reactive lymphoid lesions 
showed an LCR ratio of less than 3. Several studies reported that the LCR ratio 
exceeded 3 in some patients with reactive lymphoid lesions such as toxoplasmosis, 
collagen disease, and rheumatoid arthritis [6,7]. However, there was no such case in our 
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series. On IDS, the LCR ratio ranged from 3 and 6 in 4 patients (follicular lymphoma 
(FL): 1, and DLBCL: 3). Of these, 3 had DLBCL, and tumor presence was 
morphologically suggested. Using IDS, we could simultaneously count cells in a single 
specimen while observing of morphological atypia. This may have contributed to the 
differentiation of lymphoma cells from reactive lymphocytes, with a cut-off of 3. 
In 4 patients, LCR was not detected on FCM, but it was detected on IDS. In 2 
(Cases 21 and 23) of these, there was no LCR when randomly counting cells on IDS-1. 
However, when counting middle- to large-sized cells under cellular-morphology 
observation on IDS-2, LCR could be detected (Figure 3). This was possibly because the 
number of tumor cells was small, and a large number of reactive lymphocytes appeared 
as background cells. Crapanzano et al.[8] conducted FCM in 6 patients with marginal 
zone B-cell lymphoma, and reported that LCR was detected in 3. It was not detected in 
the other 3 patients, possibly because the number of background cells was large, and 
that of lymphoma cells was small, as indicated in our study. 
In addition, the reasons why LCR could not be detected on FCM include the 
fragility of large lymphoma cells [14,16,17]. Verstovsek et al.[18] reviewed patients 
with false-negative reactions on FCM, and indicated that 27% of patients with DLBCL 
showed false-negative reactions on FCM. Such reactions were related to cellular 
degeneration in 75%. In Case 32 (Figure 4), marked cellular degeneration occurred in 
the sample treatment process, and LCR was not detected on FCM. IDS-2 facilitated the 
detection of LCR through morphological differentiation between cellular 
degeneration-related enucleated cells/non-specific reactions and degeneration-free 
tumor cells. 
In 1 patient with follicular lymphoma (Case 19), there was no LCR on FCM. 
However, LCR was noted on IDS with the same sample. The reasons were IDS 
detected the cytoplasmic immunoglobulin. 
Several studies classified the histological type by combining FCM with fine 
needle aspiration (FNA)[13-19]. In residual samples after cytological diagnosis, FCM 
analysis was conducted to estimate the histological type. 
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Conclusion 
The LCR detection rate of IDS was similar to or higher than that of FCM. 
Therefore, the combination of FNA and IDS may improve the accuracy of B-cell 
lymphoma diagnosis, assisting FCM/ cytological diagnosis. 
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Figure 1.  Negative control case; Immunocytochemical double staining(IDS) of  Hodgkin 
lymphoma (case 17) IDS-1:κ/λ rate  1.1 
 The Kappa (red) and Lambda (brown) reactions of small- to middle-sized lymphocytes were similar. 
No light-chain restriction was detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Immunocytochemical double staining of Follicular lymphoma (case 18); 
IDS-1: κ/λ rate 6.2  
 Most cells were positive for Kappa, and light-chain restriction was detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3. case 23 Follicular lymphoma grade3; κ/λ rate (FCM:1.5/IDS-1:1.6/IDS-2:3.2)  
A: There was no light-chain restriction in any FCM gating cell.                 
B: There was no light-chain restriction in any small lymphocyte. However, large 
atypical cells were positive for Lambda alone (brown, arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. case32 diffuse large B-cell lymphomas; κ/λ rate (FCM:1.2/IDS-1:3.3 
/IDS-2:24) A: A large number of degenerative cells were observed in the FCM gating. No 
light-chain restriction was detected. B: In the background, there were a large number of 
naked cells.Large, irregular, Lambda (brown)-positive cells were observed. Small 
lymphocytes were positive for Kappa (red). 
C: Large lymphoma cells were positive for Lambda (brown).  
 
Table 1  Percentage of Flow Cytometry and Immunocytochemical double stain 
    Flow Cytometry  Immunocytochemical double stain 
            IDS-1(random) IDS-2(medium-large)
case 
NO 
Histopathology CD20 κ λ 
κ/λ  
or    
λ / κ 
κ λ 
κ/λ  
or    
λ / κ 
 κ λ 
κ/λ  
or    
λ / κ 
1 Reactive 51.2 17.4 12.1 1.4 23.7 29 1.2  24 44 1.8 
2 Reactive   - - - 19 13 1.5  36 23 1.5 
3 Reactive   - - - 20.1 12 1.7  32 22 1.5 
4 Reactive 75.3 33.1 28.5 1.2 44.6 25 1.8  25 12 2.1 
5 Reactive 63.4 30 26 1.2 21.8 28 1.3  16 19 1.2 
6 Reactive   - - - 33.4 21 1.6  37 34 1.1 
7 Reactive 40.1 14.8 14.9 1 9.6 9.4 1  32 20 1.6 
8 Reactive 50.4 24.7 20.3 1.2 5 3.2 1.6  6 3 2 
9 Reactive 75.5 36.5 36.7 1 3.8 2.6 1.5  7 6 1.2 
10 Reactive 65.1 36.2 28.4 1.3 38.2 33 1.1  33 61 1.9 
11 Reactive 33 17.6 14.4 1.2 25.6 25 1  29 31 1.1 
12 Reactive 37.4 16.8 16.2 1 9 10 1.1  6 8 1.3 
13 Reactive   - - - 5.6 2.8 2  15 9 1.6 
14 T-LBL 7.5 3.5 4.6 1.3 3.4 4.6 1.4  1 2 2 
15 PTCL 28 13 8.6 1.5 15.3 17 1.1  24 44 1.8 
16 HL 40.2 19 17 1.1 27.4 20 1.3  44 44 1 
17 HL 51.4 29 22 1.4 22.6 20 1.1  33 40 1.2 
18 FL 87.9 87.1 3.9 22.3 57.8 9.2 6.2  90.5 9.5 9.5 
19 FL 68.9 6.4 4.3 1.5 35 6.2 5.6  32 6 5.3 
20 FL 72.4 1 56 56 1 30.3 30  1 23 23 
21 FL 82 4.9 3.8 1.3 9.5 9.2 1  10.5 50 4.8 
22 FL 83.8 1.4 57 41 5.7 37.7 6.6  7 42 6 
23 FL 50.9 20.4 14 1.5 26.2 15.8 1.6  12 38.6 3.2 
24 FL 94.3 2.6 1.4 1.9 23 27.6 1.2  40.5 26 1.6 
25 FL 72.3 8.1 66 8.1 8.8 77.5 8.8  1 45 45 
26 DLBCL 44.1 56 7.8 7.2 9 8.1 1.1  71 11 6.4 
27 DLBCL 96 82 2.6 31 53 1 53  88 1 88 
28 DLBCL 33.4 2.6 68 26 19 38.8 2  21 64 3 
29 DLBCL 98.1 99 1.1 90 88 1 88  92.5 1 93 
30 DLBCL 95.7 89.1 8.3 10.7 55 3.2 17  56 8 7 
31 DLBCL 29.9 25 27 1.1 6.8 3.4 2  49 26 1.9 
32 DLBCL 28.2 29 25 1.2 4 13 3.3  0 24 24 
33 DLBCL 92 77 17 4.5 22 12.6 1.7  69.5 15 4.6 
34 DLBCL 78.5 3.2 84 26 7 59.2 8.5  14 72 5.1 
35 ML   - - - 100 1 100  100 1 100 
36 LP 24.3 79 1 79 76 4 19  100 1 100 
37 PM   - - - 1 100 100  1 100 100 
38 MCL 93.8 92 1 92 90 2.4 38  90 8.5 11 
39 BLL 99.5 99 1 99 100 1 100  100 1 100 
40 ML 37.1 1 22.5 22.5 7.2 6.2 1.2  54 4 14 
 A value of 1 or less was defined as 1.                                                                          
T-LBL:T-lymphoblastic lymphoma PTCL: peripheral T-cell  lymphoma HL: Hodgkin's lymphoma FL:follicular lymphoma  
DLBCL:diffuse larg B cell lymphoma    ML:malignant lymphomaNOS  LP:lymphoplasmacytic lymphoma  PM: plasma cell 
myeloma   MCL:mantle cell lymphoma  BLL: Burkitt-like  lymphoma  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2  Negative control * (n=17) 
κ:λ ratio 
  LCRr case range median 
FCM <3 17 1-1.5 (1.2) 
IDS-1 <3 17 1-2 (1.3) 
IDS-2 <3 17 1-2.1 (1.5) 
* Negative control : reactive lesion, T cell lymphoma, Hodgkin lymphoma 
 LCRr : light-chain restriction ratio (κ/λ ratio or λ/κ ratio ) 
FCM : Flow cytometry 
IDS-1 : Immunocytochemical double staining (random) 
IDS-2 : Immunocytochemical double staining (medium-large) 
 
 
 
 
 
 
Table 3  light-chain restriction ratio of B-cell 
lymphomas 
      κ:λ ratio 
      range  median 
FCM (n=21) <3 6 (28.6%) 1.1-1.9 (1.5) 
>3 15 (71.4%) 4.5 - 99 (22.5) 
IDS-1(n=23) <3 8 (34.7%) 1-2 (1.2) 
>3 15(65.2%) 3.3-100 (24.5) 
IDS-2(n=23) <3 2 (8.6 %) 1.6-1.9 (1.7) 
  >3 21 (91.3%) 3-100 (17) 
LCRr : light-chain restriction ratio (κ/λ ratio or λ/κ ratio ) 
FCM : Flow cytometry 
IDS-1 : Immunocytochemical double staining (random) 
IDS-2 : Immunocytochemical double staining (medium-large) 
 
 
 
 
 
 
Table4  light-chain restriction ratio of B-cell lymphomas 
         Comparison of FCM and IDS (n＝21）   
  method   
Method pattern FCM IDS-1 IDS-2 case 
FCM detected - - 0 
FCM ・IDS-1 detected detected - 0 
FCM ・IDS-1 ・IDS-2 detected detected detected 11 （52.3%） 
FCM ・IDS-2 detected - detected 4 （19.0%） 
IDS-1 ・IDS-2 - detected detected 3 （14.2%） 
IDS-2 - - detected 1 （4.8%） 
negative - - - 2 （9.5%） 
LCR : light-chain restriction 
FCM : Flow cytometry 
IDS-1 : Immunocytochemical double staining (random) 
IDS-2 : Immunocytochemical double staining (medium-large) 
 
 
 
Table 5  Evaluation of LCR in FCM and IDS 
FCM IDS-1 IDS-2
Sensitivity 71.4% 65.2% 91.3%
Specificity 100% 100% 100%
Positive Predictive Value 100% 100% 100%
Negative Predictive Value 68.4% 68.0% 89.4%
LCR : light-chain restriction 
IDS-1 : Immunocytochemical double staining (random) 
IDS-2 : Immunocytochemical double staining (medium-large) 
 
 
 
 
 
 
 
 
